Key facts
- Arthrone’s last known valuation is $111.0M (Aug 2023).
- It has raised $51.1M; the latest was Later Stage VC ($21.8M) in Apr 2026.
- Notable investors include Addor Capital, Cowin Capital, Founder Hesheng Investment, SAIF Partners, CDIB Capital International — 19 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 19 names
- ·Watchlist + deal alerts for Arthrone
- ·The full record, as it builds
Funding rounds
No funding rounds for Arthrone are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Arthrone
Developer and manufacturer of orthopaedic medical devices designed to restore joint function and treat musculoskeletal conditions. The company offers ceramic-based joint prostheses, spine and dental implants, and sports medicine devices, enabling healthcare providers to perform precise surgical interventions and improve patient mobility outcomes.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2017
- Employees
- 43
- Website
- arthrone.com/
- Ownership
- Privately Held (backing)
Arthrone doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Arthrone shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Arthrone in its N-PORT filings yet. We sweep new filings monthly.